Plasma levels of high-density lipoprotein (HDL) cholesterolare inversely related to the incidence of coronary heart diseaseand stroke. The lowering of low-density lipoprotein (LDL) cholesterolwith statin therapy reduces the risk of atherosclerotic cardiovasculardisease but only by about one third. These findings have ledto the idea that raising HDL cholesterol might be a treatmentfor atherosclerosis. On the basis of the high-HDL phenotypeof a human genetic deficiency of cholesteryl ester transferprotein (CETP),1 a new class of drugs that inhibit CETP wasdeveloped.2 Although the CETP inhibitor torcetrapib is effectiveat raising HDL cholesterol levels, it . . . [Full Text of this Article]
Source Information
From the Department of Medicine, Columbia University, New York.
This article (10.1056/NEJMe078029) was published at www.nejm.org on March 26, 2007.
This article has been cited by other articles:
Seiler, S., Schlitt, A., Jiang, X.-C., Ulrich, C., Blankenberg, S., Lackner, K. J., Girndt, M., Werdan, K., Buerke, M., Fliser, D., Heine, G. H.
(2008). Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V. Nephrol Dial Transplant
23: 3599-3604
[Abstract][Full Text]
Su, Y. R., Blakemore, J. L., Zhang, Y., Linton, M. F., Fazio, S.
(2008). Lentiviral Transduction of ApoAI Into Hematopoietic Progenitor Cells and Macrophages: Applications to Cell Therapy of Atherosclerosis. Arterioscler. Thromb. Vasc. Bio.
28: 1439-1446
[Abstract][Full Text]
Thompson, A., Di Angelantonio, E., Sarwar, N., Erqou, S., Saleheen, D., Dullaart, R. P. F., Keavney, B., Ye, Z., Danesh, J.
(2008). Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk. JAMA
299: 2777-2788
[Abstract][Full Text]
Ibanez, B., Vilahur, G., Cimmino, G., Speidl, W. S., Pinero, A., Choi, B. G., Zafar, M. U., Santos-Gallego, C. G., Krause, B., Badimon, L., Fuster, V., Badimon, J. J.
(2008). Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.. J Am Coll Cardiol
51: 1104-1109
[Abstract][Full Text]
Lavie, C. J., Milani, R. V.
(2008). Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era.. J Am Coll Cardiol
51: 56-58
[Full Text]
Zeller, M., Masson, D., Farnier, M., Lorgis, L., Deckert, V., Pais de Barros, J.-P., Desrumaux, C., Sicard, P., Grober, J., Blache, D., Gambert, P., Rochette, L., Cottin, Y., Lagrost, L.
(2007). High Serum Cholesteryl Ester Transfer Rates and Small High-Density Lipoproteins Are Associated With Young Age in Patients With Acute Myocardial Infarction. J Am Coll Cardiol
50: 1948-1955
[Abstract][Full Text]
Cuchel, M., Rader, D. J.
(2007). Is the Cholesteryl Ester Transfer Protein Proatherogenic or Antiatherogenic in Humans?. J Am Coll Cardiol
50: 1956-1958
[Full Text]
Gilbert, R. E.
(2007). Rosiglitazone: Opening Pandora's Black Box?. CJASN
2: 1329-1331
[Full Text]
Porchay-Balderelli, I., Pean, F., Bellili, N., Jaziri, R., Marre, M., Fumeron, F., for the DIABHYCAR Study Group,
(2007). The CETP TaqIB Polymorphism Is Associated With the Risk of Sudden Death in Type 2 Diabetic Patients. Diabetes Care
30: 2863-2867
[Abstract][Full Text]
Lindsay, A.
(2007). JournalScan. Heart
93: 1008-1010
[Full Text]
(2007). Torcetrapib Does Not Limit Atherosclerosis Progression. Journal Watch Cardiology
2007: 2-2
[Full Text]
Previous
